HRP20220860T1 - Cxcr4 vezujuće molekule - Google Patents
Cxcr4 vezujuće molekule Download PDFInfo
- Publication number
- HRP20220860T1 HRP20220860T1 HRP20220860TT HRP20220860T HRP20220860T1 HR P20220860 T1 HRP20220860 T1 HR P20220860T1 HR P20220860T T HRP20220860T T HR P20220860TT HR P20220860 T HRP20220860 T HR P20220860T HR P20220860 T1 HRP20220860 T1 HR P20220860T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- set forth
- sequence set
- region consists
- polypeptide
- Prior art date
Links
- 101150066398 CXCR4 gene Proteins 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 claims 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims 10
- 101710082513 C-X-C chemokine receptor type 4 Proteins 0.000 claims 4
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims 4
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 1
- 230000006229 amino acid addition Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 102000053523 human CXCR4 Human genes 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2228—Corticotropin releasing factor [CRF] (Urotensin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—HIV or HTLV
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/521—Chemokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/285—Demyelinating diseases; Multipel sclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/323—Arteriosclerosis, Stenosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Tropical Medicine & Parasitology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2015900054A AU2015900054A0 (en) | 2015-01-09 | CXCR4 binding molecules | |
| EP16734863.0A EP3242685B1 (en) | 2015-01-09 | 2016-01-08 | Cxcr4 binding molecules |
| PCT/AU2016/050005 WO2016109872A1 (en) | 2015-01-09 | 2016-01-08 | Cxcr4 binding molecules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220860T1 true HRP20220860T1 (hr) | 2022-10-14 |
Family
ID=56355354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220860TT HRP20220860T1 (hr) | 2015-01-09 | 2016-01-08 | Cxcr4 vezujuće molekule |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10538596B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3242685B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP6863897B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN114478773A (cg-RX-API-DMAC7.html) |
| AU (3) | AU2016206191B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2973317A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK3242685T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2924394T3 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20220860T1 (cg-RX-API-DMAC7.html) |
| LT (1) | LT3242685T (cg-RX-API-DMAC7.html) |
| SG (2) | SG10202111844VA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016109872A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3242685T (lt) * | 2015-01-09 | 2022-08-25 | Adalta Limited | Cxcr4 surišančios molekulės |
| CN116903741A (zh) | 2016-06-20 | 2023-10-20 | 科马布有限公司 | 特异性结合于pd-l1的抗体或其抗原结合片段及其用途 |
| CA3042853A1 (en) | 2016-11-07 | 2018-05-11 | Crossbeta Biosciences B.V. | Novel amyloid beta oligomer specific binding molecule |
| WO2018130702A1 (en) * | 2017-01-16 | 2018-07-19 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Improved multi tyrosine kinase inhibitor therapy |
| JP7517986B2 (ja) * | 2017-12-19 | 2024-07-17 | ジーピーシーアール セラピューティクス，インク． | Ｇｐｃｒヘテロマー阻害剤及びその用途 |
| WO2020205836A1 (en) * | 2019-04-02 | 2020-10-08 | Eli Lilly And Company | Methods of selecting and detecting binding peptides |
| KR20210156849A (ko) * | 2019-05-17 | 2021-12-27 | 주식회사 지피씨알 | Gpcr 헤테로머 저해제들 및 이의 용도 |
| JP7365674B2 (ja) * | 2019-08-29 | 2023-10-20 | 国立大学法人 長崎大学 | アスペルギローマモデル非ヒト動物 |
| CN110804100A (zh) * | 2019-11-01 | 2020-02-18 | 中国人民解放军陆军特色医学中心 | 融合多肽及其在增强干细胞归巢能力和抗凋亡能力中的应用和药物组合物 |
| CA3175055A1 (en) * | 2020-03-13 | 2021-09-16 | Julius-Maximilians-Universitat Wurzburg | Affinity matured and humanized binding domains targeting ror2 |
| WO2023092177A1 (en) * | 2021-11-23 | 2023-06-01 | Adalta Limited | Rank-l binding molecules |
| CN114533884A (zh) * | 2022-04-20 | 2022-05-27 | 澳门大学 | 一种联合治疗癌症的药物及s100a9-cxcl12信号抑制剂的应用 |
| WO2025010469A1 (en) * | 2023-07-07 | 2025-01-16 | Adalta Limited | Linking receptor occupancy to efficacy of cxcr4 antagonists |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4439A (en) | 1846-04-04 | Improvement in cleansing fish-oils | ||
| US4475A (en) | 1846-04-25 | Henry johnson | ||
| US196A (en) | 1837-05-15 | Machine for mowing and heaping grain | ||
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US5206154A (en) | 1985-01-28 | 1993-04-27 | Xoma Corporation | Method of producing cecropins by microbiological techniques |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US5215896A (en) | 1987-03-20 | 1993-06-01 | Creative Biomolecules, Inc. | Leader sequences for the production of recombinant proteins |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| SE8804074D0 (sv) | 1988-11-10 | 1988-11-10 | Pharmacia Ab | Sensorenhet och dess anvaendning i biosensorsystem |
| FI903489A0 (fi) | 1988-11-11 | 1990-07-10 | Medical Res Council | Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna. |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5194594A (en) | 1990-09-07 | 1993-03-16 | Techniclone, Inc. | Modified antibodies |
| DK0564531T3 (da) | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| ATE233817T1 (de) | 1992-08-21 | 2003-03-15 | Univ British Columbia | Kationische peptide und verfahren zu deren herstellung |
| US5648244A (en) | 1993-09-27 | 1997-07-15 | President And Fellows Of Harvard College | Production, purification, cleavage and use of fusion peptides |
| US5485277A (en) | 1994-07-26 | 1996-01-16 | Physical Optics Corporation | Surface plasmon resonance sensor and methods for the utilization thereof |
| US6037145A (en) | 1994-09-07 | 2000-03-14 | Suntory Limited | Process for production of protein |
| US5567301A (en) | 1995-03-01 | 1996-10-22 | Illinois Institute Of Technology | Antibody covalently bound film immunobiosensor |
| US5972639A (en) | 1997-07-24 | 1999-10-26 | Irori | Fluorescence-based assays for measuring cell proliferation |
| DE19818790A1 (de) | 1998-04-27 | 1999-10-28 | Affina Immuntechnik Gmbh | Immunadsorptionsmatrix, Verfahren zu ihrer Herstellung und ihre Verwendung |
| DE69907439T3 (de) | 1998-05-06 | 2014-01-02 | Genentech, Inc. | Reinigung von proteinen durch ionenaustauschchromatographie |
| WO2000006763A1 (en) | 1998-07-31 | 2000-02-10 | Pierce Chemical Company | Fusion products containing insoluble proteinaceous tag |
| US6190908B1 (en) | 1998-08-12 | 2001-02-20 | The Scripps Research Institute | Modulation of polypeptide display on modified filamentous phage |
| US6306610B1 (en) | 1998-09-18 | 2001-10-23 | Massachusetts Institute Of Technology | Biological applications of quantum dots |
| US6242219B1 (en) | 1999-03-18 | 2001-06-05 | Xoma (Us) Llc | Methods for recombinant peptide production |
| JP2003504014A (ja) | 1999-06-30 | 2003-02-04 | エボテック オーアーイー アクチェンゲゼルシャフト | ウイルス状粒子、それらの調製及び好ましくは薬学的スクリーニング及び機能的ゲノムにおけるそれらの使用 |
| US20050287153A1 (en) | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
| US20060228364A1 (en) | 1999-12-24 | 2006-10-12 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
| CA2406873A1 (en) | 2000-04-25 | 2001-11-01 | Chemicon International, Inc. | Cell proliferation assay |
| WO2002026292A1 (de) | 2000-09-28 | 2002-04-04 | Affina Immuntechnik Gmbh | Durchflussvorrichtung zum trennen von substanzen in körperflüssigkeiten, insbesondere blut und dessen verwendung |
| DK1532261T3 (da) | 2002-05-24 | 2010-05-31 | Medtronic Inc | Fremgangsmåder og DNA-konstrukter til produktion af polypeptider med højt udbytte |
| US8574590B2 (en) | 2003-07-30 | 2013-11-05 | Integral Molecular, Inc. | Lipoparticles comprising proteins, methods of making, and using the same |
| WO2005108415A2 (en) * | 2004-04-30 | 2005-11-17 | Biogen Idec Ma Inc. | Membrane associated molecules |
| JP2008500830A (ja) | 2004-06-01 | 2008-01-17 | ドマンティス リミテッド | 増加した血清半減期を有する二重特異性融合抗体 |
| CA2567655C (en) * | 2004-06-02 | 2015-06-30 | Diatech Pty Ltd | Binding moieties based on shark ignar domains |
| WO2007115232A2 (en) | 2006-03-30 | 2007-10-11 | Chemocentryx, Inc. | Cxcr4 modulators |
| US7807704B2 (en) | 2006-03-30 | 2010-10-05 | Chemocentryx, Inc. | Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 |
| RS55740B1 (sr) * | 2006-10-02 | 2017-07-31 | Squibb & Sons Inc | Humana antitela koja se vezuju za cxcr4 i njihove upotrebe |
| US8088895B2 (en) | 2006-10-18 | 2012-01-03 | Chemocentryx, Inc. | Antibodies that bind CXCR7 epitopes |
| CN101657715B (zh) | 2006-11-10 | 2012-07-25 | 戴麦里克斯生物科学有限公司 | 检测系统及其应用 |
| US20080261978A1 (en) | 2007-03-08 | 2008-10-23 | Clark Michael P | Chemokine receptor modulators |
| EP2252318A4 (en) * | 2008-03-20 | 2012-04-18 | Carolus Therapeutics Inc | PROCESS FOR TREATMENT OF IGNITION |
| US20100136584A1 (en) * | 2008-09-22 | 2010-06-03 | Icb International, Inc. | Methods for using antibodies and analogs thereof |
| US20100092470A1 (en) * | 2008-09-22 | 2010-04-15 | Icb International, Inc. | Antibodies, analogs and uses thereof |
| DK2349273T3 (en) | 2008-11-04 | 2015-07-13 | Chemocentryx Inc | Modulators of CXCR7 |
| WO2011083141A2 (en) | 2010-01-08 | 2011-07-14 | Ablynx Nv | Method for generation of immunoglobulin sequences by using lipoprotein particles |
| DK2776032T3 (en) * | 2011-11-09 | 2019-02-04 | Bristol Myers Squibb Co | TREATMENT OF HEMATOLOGICAL MALIGNITIES WITH ANTI-CXCR4 ANTIBODY |
| EP2964332A4 (en) * | 2013-03-08 | 2016-09-14 | Curonz Holdings Company Ltd | NEURAL REGENERATION PEPTIDES AND USES THEREOF |
| LT3242685T (lt) * | 2015-01-09 | 2022-08-25 | Adalta Limited | Cxcr4 surišančios molekulės |
-
2016
- 2016-01-08 LT LTEPPCT/AU2016/050005T patent/LT3242685T/lt unknown
- 2016-01-08 SG SG10202111844VA patent/SG10202111844VA/en unknown
- 2016-01-08 SG SG11201705583XA patent/SG11201705583XA/en unknown
- 2016-01-08 DK DK16734863.0T patent/DK3242685T3/da active
- 2016-01-08 US US15/542,060 patent/US10538596B2/en active Active
- 2016-01-08 ES ES16734863T patent/ES2924394T3/es active Active
- 2016-01-08 CN CN202210051480.9A patent/CN114478773A/zh not_active Withdrawn
- 2016-01-08 AU AU2016206191A patent/AU2016206191B2/en active Active
- 2016-01-08 CN CN201680010938.9A patent/CN107427574B/zh active Active
- 2016-01-08 WO PCT/AU2016/050005 patent/WO2016109872A1/en not_active Ceased
- 2016-01-08 CA CA2973317A patent/CA2973317A1/en active Pending
- 2016-01-08 EP EP16734863.0A patent/EP3242685B1/en active Active
- 2016-01-08 HR HRP20220860TT patent/HRP20220860T1/hr unknown
- 2016-01-08 EP EP22171019.7A patent/EP4112077A1/en active Pending
- 2016-01-08 JP JP2017536271A patent/JP6863897B2/ja active Active
-
2017
- 2017-10-31 AU AU2017254863A patent/AU2017254863A1/en not_active Abandoned
-
2019
- 2019-05-20 AU AU2019203511A patent/AU2019203511B2/en active Active
- 2019-12-18 US US16/719,125 patent/US11142588B2/en active Active
-
2020
- 2020-07-16 JP JP2020121974A patent/JP7212009B2/ja active Active
-
2022
- 2022-11-11 JP JP2022181132A patent/JP2023015277A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4112077A1 (en) | 2023-01-04 |
| CN107427574A (zh) | 2017-12-01 |
| AU2016206191A9 (en) | 2017-01-19 |
| US10538596B2 (en) | 2020-01-21 |
| US11142588B2 (en) | 2021-10-12 |
| AU2016206191B2 (en) | 2017-08-03 |
| US20200231708A1 (en) | 2020-07-23 |
| ES2924394T3 (es) | 2022-10-06 |
| JP2023015277A (ja) | 2023-01-31 |
| LT3242685T (lt) | 2022-08-25 |
| EP3242685B1 (en) | 2022-05-04 |
| CA2973317A1 (en) | 2016-07-14 |
| AU2019203511A1 (en) | 2019-06-06 |
| DK3242685T3 (da) | 2022-07-25 |
| AU2019203511B2 (en) | 2021-08-12 |
| SG10202111844VA (en) | 2021-12-30 |
| JP2018504112A (ja) | 2018-02-15 |
| CN107427574B (zh) | 2022-02-08 |
| AU2017254863A1 (en) | 2017-11-16 |
| JP6863897B2 (ja) | 2021-04-21 |
| AU2016206191A1 (en) | 2016-12-15 |
| JP7212009B2 (ja) | 2023-01-24 |
| WO2016109872A1 (en) | 2016-07-14 |
| EP3242685A4 (en) | 2018-07-11 |
| JP2020182479A (ja) | 2020-11-12 |
| SG11201705583XA (en) | 2017-08-30 |
| CN114478773A (zh) | 2022-05-13 |
| US20180072816A1 (en) | 2018-03-15 |
| EP3242685A1 (en) | 2017-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20220860T1 (hr) | Cxcr4 vezujuće molekule | |
| HRP20241268T1 (hr) | Trispecifični proteini i postupci primjene | |
| HRP20251304T1 (hr) | Anti-c1s protutijela i postupci njihove upotrebe | |
| HRP20190472T1 (hr) | Klaudin-6 specifični imunoreceptori i t-stanični epitopi | |
| JP2018504112A5 (cg-RX-API-DMAC7.html) | ||
| JP2014221758A5 (cg-RX-API-DMAC7.html) | ||
| FI3294333T4 (fi) | Klaudiini-18.2-spesifiset immunoreseptorit ja t-soluepitoopit | |
| JP2020501550A5 (cg-RX-API-DMAC7.html) | ||
| JP2019511222A5 (cg-RX-API-DMAC7.html) | ||
| JP2005506035A5 (cg-RX-API-DMAC7.html) | ||
| HRP20201528T1 (hr) | Biparatopikalni polipeptidi koji antagoniziraju wnt signalizaciju u tumorskim stanicama | |
| HRP20250624T1 (hr) | Sredstva, uporaba i metode za liječenje sinukleinopatije | |
| RU2017134456A (ru) | Рекомбинантные связывающие белки и их применение | |
| JP2018522563A5 (cg-RX-API-DMAC7.html) | ||
| HRP20220811T1 (hr) | Agonistička sredstva za vezanje tnf receptora | |
| HRP20160020T1 (hr) | Postupak za aktiviranje pomagaäśke t stanice i pripravak za uporabu u postupku | |
| PH12021550001A1 (en) | Novel fusion protein specific for cd137 and pd-l1 | |
| JP2019508013A5 (cg-RX-API-DMAC7.html) | ||
| HRP20041108B1 (hr) | Peptidi povezani sa tumorom koji se vežu na mhc molekule | |
| ES2926511T3 (es) | Anticuerpos anti-CLEVER-1 humanizados y utilización de los mismos | |
| RU2017114673A (ru) | Слитый белок, наночастица, состоящая из множества мономеров указанного слитого белка, и их применение | |
| BRPI0714844B8 (pt) | molécula de ácido nucleico e seus usos, composição farmaceutica e complexo | |
| HRP20150664T1 (hr) | Antikancerogeni fuzijski protein | |
| JPWO2020063488A5 (cg-RX-API-DMAC7.html) | ||
| EA201990885A1 (ru) | Композиции, содержащие короткие пептиды, полученные из pedf, и их применение |